Poster session 20

Programm

• 15:30 – 15:35 3 Min. 2 Min.

  • ePoster
  • P257

  Switching from anti-CGRP-receptor mAb (erenumab) to an anti-CGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study

  • Valeria Caponnetto (L'Aquila/ IT)

   CGRP inhibitors in the clinic, Migraine
• 15:35 – 15:40 3 Min. 2 Min.

  • ePoster
  • P258

  REAL-WORLD FREMANEZUMAB EXPERIENCE FROM HEADACHE CLINIC IN MOSCOW

  • Alikhan Uzhakhov (Moscow/ RU)

   CGRP inhibitors in the clinic, Migraine
• 15:40 – 15:45 3 Min. 2 Min.

  • ePoster
  • P259

  Discontinuation after one-year of treatment with anti-CGRP antibodies did not provide long-term sustained response without therapy

  • Luigi Francesco Iannone (Florence/ IT)

   CGRP inhibitors in the clinic, Migraine
• 15:45 – 15:50 3 Min. 2 Min.

  • ePoster
  • P260

  Anti-CGRP monoclonal antibodies and peripheral sensitization: a study on Pressure Pain Threshold in migraineurs

  • Gabriele Garascia (Trieste/ IT)

   CGRP inhibitors in the clinic, Migraine
• 15:50 – 15:55 3 Min. 2 Min.

  • ePoster
  • P261

  Clinical characteristics, efficacy and safety of patients older than 65 years with the use of anti-CGRP drugs in the central region of Spain

  • Alicia Gonzalez-Martinez (Madrid/ ES)

   CGRP inhibitors in the clinic, Headache in the elderly
• 15:55 – 16:00 3 Min. 2 Min.

  • ePoster
  • P262

  Is it worth switching monoclonal antibodies?

  • Elsa Parreira (Amadora/ PT)

   CGRP inhibitors in the clinic, Migraine
• 16:00 – 16:05 3 Min. 2 Min.

  • ePoster
  • P263

  Study on the presence of comorbidities in a series of 200 patients with migraine and their influence on the effectiveness of fremanezumab.

  • Noemí Morollón Sánchez-Mateo (Barcelona/ ES)

   CGRP inhibitors in the clinic, Migraine
• 16:05 – 16:10 3 Min. 2 Min.

  • ePoster
  • P264

  Predictors of galcanezumab response in Korean patients with migraine

  • Miji Lee (Seoul/ KR)

   CGRP inhibitors in the clinic, Migraine
• 16:10 – 16:15 3 Min. 2 Min.

  • ePoster
  • P265

  Can We Descriminate Migraine Susceptibile to CGRP Antagonism?

  • Marjan Zaletel (Grosuplje/ SI)

   CGRP inhibitors in the clinic, Migraine
• 16:15 – 16:20 3 Min. 2 Min.

  • ePoster
  • P266

  Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study

  • Messoud Ashina (Copenhagen/ DK)

   CGRP inhibitors in the clinic, Migraine
• 16:20 – 16:25 3 Min. 2 Min.

  • ePoster
  • P267

  Response patterns in migraine patients in prophylactic treatment with different anti-CGRP pharmacological blockade systems

  • Francesca Schiano di Cola (Brescia/ IT)

   CGRP inhibitors in the clinic, Migraine
• 16:25 – 16:30 3 Min. 2 Min.

  • ePoster
  • P268

  Effect of Galcanezumab in Migraine and Concomitant Medication Overuse Headache Without Prior Drug Withdrawal

  • Javier A. Membrilla (Madrid/ ES)

   CGRP inhibitors in the clinic, Migraine
• 16:30 – 16:35 3 Min. 2 Min.

  • ePoster
  • P269

  Factors associated with favorable outcome in galcanezumab treatment for chronic migraine: A clinic-based prospective study

  • Byung-kun Kim (Seoul/ KR)

   CGRP inhibitors in the clinic, Migraine
• 16:35 – 16:40 3 Min. 2 Min.

  • ePoster
  • P270

  Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study

  • Messoud Ashina (Copenhagen/ DK)

   CGRP inhibitors in the clinic, Migraine
• 16:40 – 16:45 3 Min. 2 Min.

  • ePoster
  • P271

  Fremanezumab in patients with refractory migraine and medication-overuse headache: the experience of a tertiary Portuguese hospital

  • Rafaela Costa (Porto/ PT)

   CGRP inhibitors in the clinic, Medication overuse headache
• 16:45 – 16:50 3 Min. 2 Min.

  • ePoster
  • P272

  Descriptive study on the presence, treatment and evolution of comorbidities in a series of 200 migraine patients treated with fremanezumab.

  • Noemí Morollón Sánchez-Mateo (Barcelona/ ES)

   CGRP inhibitors in the clinic, Migraine
• 16:50 – 16:55 3 Min. 2 Min.

  • ePoster
  • P273

  Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study

  • Charly Gaul (Frankfurt a. M./ DE)

   CGRP inhibitors in the clinic, Migraine
• 16:55 – 17:00 3 Min. 2 Min.

  • ePoster
  • P274

  Could Symptom Severity Predict the Response to Anti-Cgrp Monoclonal Antibodies in Migraine?

  • Javier A. Membrilla (Madrid/ ES)

   CGRP inhibitors in the clinic, Migraine